Skip to main content
SpringerLink
Log in

Standard- und experimentelle Therapie kutaner T-Zell-Lymphome

  • Leitthema
  • Published:
Der Hautarzt Aims and scope Submit manuscript

Zusammenfassung

Kutane T-Zell-Lymphome umfassen eine Gruppe von Krankheiten mit dem Merkmal einer Invasion von monoklonalen T-Lymphozyten in die Haut. Aufgrund klinischer, histologischer und immunhistochemischer Merkmale können die kutanen T-Zell-Lymphome in 3 Gruppen eingeteilt werden: Indolente mit einer Überlebenszeit von >10 Jahren, aggressive mit einer Überlebenszeit von <10 Jahren sowie provisorisch eingeteilte Formen (EORTC-Klassifikation). Herkömmliche Therapien wie PUVA, Ganzhautbestrahlung mit schnellen Elektronen, Methotrexat, Polychemotherapie, Retinoiden sowie Photopherese werden seit vielen Jahren eingesetzt. Neu zugelassen ist Bexaroten. Im Streben nach besseren Ansprechraten werden im Rahmen von Studien neue Medikamente wie Imiquimod, Denileukin-diftitox, liposomales Doxorubicin und Adeno-Interferon-γ sowie Kombinationen der verschiedenen Therapiemodalitäten untersucht.

Abstract

Cutaneous T-cell lymphoma represent a heterogeneous group of diseases characterized by skin invasion of monoclonal T-lymphocytes. These cutaneous T-cell lymphomas are divided into 3 groups based on clinical, histological and immunohistological characteristics: Indolent with a survival time of over 10 years, aggressive with a survival time less than 10 years and provisional (EORTC classification). Standard treatments such as PUVA, total skin electron beam, methotrexate, polychemotherapy regimens, retinoids and photopheresis have been used for years. Bexarotene is a newly registered drug. To achieve better response rates, several new drugs are being evaluated in clinical trails, including imiquimod, denileukon-diftitox, liposomal doxorubicin, adeno-interferon-γ and various combination approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abbreviations

ADO:

Arbeitsgemeinschaft Dermatologische Onkologie

CBCL:

kutane B-Zell-Lymphome

CTCL:

kutane T-Zell-Lymphome

EORTC:

European Organization for Research and Treatment of Cancer

FDA:

Food and Drug Administration

IFN:

Interferon

IL:

Interleukin

MHC:

„major histocompatibility complex“

PUVA:

Psoralen und UVA-Behandlung

Literatur

  1. Breneman D, Duvic M, Kuzel T et al. (2002) Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol 138:325–232

    CAS  PubMed  Google Scholar 

  2. Bunn PA Jr, Ihde DC, Foon KA (1986) The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas. Cancer 57:1689–1695

    Google Scholar 

  3. Coors EA, von den Driesch P (2000) Treatment of erythrodermic cutaneous T-cell lymphoma with intermittent chlorambucil and fluocortolone therapy. Br J Dermatol 143:127–131

    CAS  PubMed  Google Scholar 

  4. Dahl MV (2002) Imiquimod: a cytokine inducer. J Am Acad Dermatol 47:S205–208

    PubMed  Google Scholar 

  5. Diederen PV, van Weelden H, Sanders CJ et al. (2003) Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides: a retrospective study. J Am Acad Dermatol 48:215–219

    Article  PubMed  Google Scholar 

  6. Dummer R, Willers J, Dobbeling U, Burg G (2001) Current pathogenetic aspects of Sezary syndrome and mycosis fungoides. Hautarzt 52:189–192

    Article  CAS  PubMed  Google Scholar 

  7. Dummer R, Urosevic M, Kempf W et al. (2003) Imiquimod induces complete clearance of a PUVA-resistant plaque in mycosis fungoides. Dermatology 207:116–118

    PubMed  Google Scholar 

  8. Duvic M, Cather JC (2000) Emerging new therapies for cutaneous T-cell lymphoma. Dermatol Clin 18:147–156

    CAS  PubMed  Google Scholar 

  9. Edelson R, Berger C, Gasparro F et al. (1987) Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med 316:297–303

    CAS  PubMed  Google Scholar 

  10. Fierro MT, Quaglino P, Savoia P et al. (1998) Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow-up study of 81 patients treated with COP or CHOP. Leuk Lymphoma 31:583–588

    CAS  PubMed  Google Scholar 

  11. Gollnick HP, Owsianowski M, Ramaker J et al. (1995) Extracorporeal photopheresis—a new approach for the treatment of cutaneous T cell lymphomas. Recent Results Cancer Res 139:409–415

    CAS  PubMed  Google Scholar 

  12. Hengge UR, Benninghoff B, Ruzicka T, Goos M (2001) Topical immunomodulators—progress towards treating inflammation, infection, and cancer. Lancet Infect Dis 1:189–198

    CAS  PubMed  Google Scholar 

  13. Herrmann JJ, Roenigk HH Jr, Hurria A et al. (1995) Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J Am Acad Dermatol 33:234–242

    CAS  PubMed  Google Scholar 

  14. Hofer A, Cerroni L, Kerl H, Wolf P (1999) Narrowband (311-nm) UV-B therapy for small plaque parapsoriasis and early-stage mycosis fungoides. Arch Dermatol 135:1377–1380

    CAS  PubMed  Google Scholar 

  15. Hoppe RT (1991) Total skin electron beam therapy in the management of mycosis fungoides. Front Radiat Ther Oncol 25:80–89; discussion 132–133

    CAS  PubMed  Google Scholar 

  16. Jones GW, Hoppe RT, Glatstein E (1995) Electron beam treatment for cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 9:1057–1076

    CAS  PubMed  Google Scholar 

  17. Kessler JF, Jones SE, Levine N et al. (1987) Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides). Arch Dermatol 123:201–204

    CAS  PubMed  Google Scholar 

  18. Knobler R, Girardi M (2001) Extracorporeal photochemoimmunotherapy in cutaneous T cell lymphomas. Ann N Y Acad Sci 941:123–138

    CAS  PubMed  Google Scholar 

  19. Knobler E, Warmuth I, Cocco C et al. (2002) Extracorporeal photochemotherapy—the Columbia Presbyterian experience. Photodermatol Photoimmunol Photomed 18:232–237

    Article  PubMed  Google Scholar 

  20. Kontochristopoulos GJ, Exadaktylou D, Hatziolou E et al. (2001) Follicular mucinosis associated with early stage cutaneous T-cell lymphoma: successful treatment with interferon alpha-2b and acitretin. J Dermatolog Treat 12:117–121

    CAS  PubMed  Google Scholar 

  21. Molineux G (2002) Pegylation: engineering improved pharmaceuticals for enhanced therapy. Cancer Treat Rev 28 [Suppl A]:13–16

  22. Olsen EA, Bunn PA (1995) Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 9:1089–1107

    CAS  PubMed  Google Scholar 

  23. Olsen EA, Rosen ST, Vollmer RT et al. (1989) Interferon alfa-2a in the treatment of cutaneous T cell lymphoma. J Am Acad Dermatol 20:395–407

    CAS  PubMed  Google Scholar 

  24. Ong C, Sullivan J, Hertzberg M, Stapleton K (2002) Stage IV CD30+ anaplastic large cell lymphoma: response to acitretin and interferon-alpha. Australas J Dermatol 43:207–210

    PubMed  Google Scholar 

  25. Rosen ST, Foss FM (1995) Chemotherapy for mycosis fungoides and the Sezary syndrome. Hematol Oncol Clin North Am 9:1109–1116

    CAS  PubMed  Google Scholar 

  26. Sentis HJ, Willemze R, Van Vloten WA (1985) Systemic polychemotherapy in patients with mycosis fungoides and lymph node involvement: a follow-up study of 17 patients. Acta Derm Venereol 65:179–183

    CAS  PubMed  Google Scholar 

  27. Sinha AA, Heald P (1998) Advances in the management of cutaneous T-cell lymphoma. Dermatol Clin 16:301–311

    CAS  PubMed  Google Scholar 

  28. Stadler R, Otte HG (1995) Combination therapy of cutaneous T cell lymphoma with interferon alpha-2a and photochemotherapy. Recent Results Cancer Res 139:391–401

    CAS  PubMed  Google Scholar 

  29. Stanley MA (2002) Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 27:571–577

    CAS  PubMed  Google Scholar 

  30. Thomsen K, Molin L, Volden G et al. (1984) 13-cis-retinoic acid effective in mycosis fungoides. A report from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol 64:563–566

    CAS  PubMed  Google Scholar 

  31. Voss N, Kim Sing C (1998) Radiotherapy in the treatment of dermatologic malignancies. Dermatol Clin 16:313–320

    CAS  PubMed  Google Scholar 

  32. Winkelmann RK, Diaz-Perez JL, Buechner SA (1984) The treatment of Sezary syndrome. J Am Acad Dermatol 10:1000–1004

    CAS  PubMed  Google Scholar 

  33. Wiskemann A, Buck C (1978) Radiotherapy of mycosis fungoides: twenty years of experience with teleroentgen and low-voltage X-ray therapy. J Dermatol Surg Oncol 4:606–610

    CAS  PubMed  Google Scholar 

  34. Wolff JM, Zitelli JA, Rabin BS et al. (1985) Intralesional interferon in the treatment of early mycosis fungoides. J Am Acad Dermatol 13:604–612

    CAS  PubMed  Google Scholar 

  35. Wollina U, Graefe T, Karte K (2000) Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin. J Am Acad Dermatol 42:40–46

    Google Scholar 

  36. Zackheim HS, Epstein EH Jr (1989) Low-dose methotrexate for the Sezary syndrome. J Am Acad Dermatol 21:757–762

    CAS  PubMed  Google Scholar 

  37. Zackheim HS, Kashani-Sabet M, Hwang ST (1996) Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients. J Am Acad Dermatol 34:626–631

    CAS  PubMed  Google Scholar 

  38. Zackheim HS, Kashani-Sabet M, Amin S (1998) Topical corticosteroids for mycosis fungoides. Experience in 79 patients. Arch Dermatol 134:949–954

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dermatologische Klinik Universitätsspital Zürich, Zürich

    M. Beyeler &  R. Dummer

  2. Dermatologische Klinik, Universitätsspital Zürich, Gloriastrasse 31, 8091 , Zürich, Schweiz

    R. Dummer

Authors
  1. M. Beyeler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Dummer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Dummer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Beyeler, M., Dummer, R. Standard- und experimentelle Therapie kutaner T-Zell-Lymphome. Hautarzt 54, 1177–1184 (2003). https://doi.org/10.1007/s00105-003-0630-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-003-0630-2

Schlüsselwörter

Keywords

Search

Navigation